Autres langues Collegium Pharmaceutical, Inc.

Actions

COLL

US19459J1043

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 03/09/2026			Varia. 5j.	Varia. 1 janv.
23,70 ^USD	-2,47%		-10,36%	-48,81%

13/08	Collegium Pharmaceutical conclut un accord de rachat d'actions accéléré de 50 millions de dollars	MT
06/08	Collegium Pharmaceutical, Inc. révise ses prévisions de résultats pour l'exercice 2026	CI

Autres langues

13/08	Collegium Pharmaceutical Enters $50 Million Accelerated Share Repurchase Agreement
13/08	Collegium Announces $50 Million Accelerated Share Repurchase Program
06/08	Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Year 2026
06/08	Collegium Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	(COLL) Collegium Pharmaceutical Expects 2026 Net Product Revenue Range $825M to $855M
06/08	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Reports Q2 Revenue $199.9M, vs. FactSet Est of $199.6M
06/08	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Posts Q2 Adjusted EPS $1.92 per Share, vs. FactSet Est of $1.72
06/08	Collegium Pharmaceutical: Q2 Earnings Snapshot
06/08	Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on July 7, 2025.
06/08	Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
06/08	Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
23/07	Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
23/07	Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
20/07	Collegium Pharmaceutical to Relocate HQ to One Lincoln in Boston
20/07	Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
05/06	Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/05	Collegium to Participate in 2026 Jefferies Global Healthcare Conference
15/05	Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director
12/05	Collegium completes acquisition of Azstarys® from Corium Therapeutics
12/05	Collegium Pharmaceutical Completes Azstarys Acquisition, Raises 2026 Net Product Revenue Guidance
12/05	Collegium Pharmaceutical, Inc. Announces Executive Changes
12/05	Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
12/05	Collegium Pharmaceutical, Inc. completed the acquisition of AZSTARYS Business of Corium, LLC.
07/05	Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Collegium Pharmaceutical : COLL Q1 2026 Earnings Presentation (Pre-Close) FINAL 05-05-26